Furthermore, DYRK1A has been implicated in neurodegenerative processes [4], certain cancers [5] and regulation of pancreatic β-cell proliferation, suggesting inhibition of DYRK1A as a novel therapeutic strategy in diabetes [6,7]. Here, DYRK1A is linked to cancer.